Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 01, 2006 (Vol. 26, No. 7)

Atlas Chromosomes in Cancer

URL:www.infobiogen.fr/services/chromcancer/index.html
  • Thorough approach
  • Haphazard in places
The Atlas Chromosomes in Cancer site is an online journal with a number of strengths. They include a focus on genes, cytogenetics, and cancer-prone diseases. Information is organized a bit haphazardly. On the plus side is access provided via clicking on a chromosome number. Other options include categories of genes, leukemias, solid tumors, and cancer-prone diseases. The site contains numerous informative case reports, which come about as close to traditional journal articles as anything on the site. I was disappointed to have to search around to find basic site info, and the totally vanilla opening page leaves something to be desired. But despite these shortcomings, many will find items of interest, here.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »